Compare Humana Inc (HUM) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs Nomura Holdings Inc — how do they compare? Humana Inc trades at $439.56 (market cap $47.61B), while Nomura Holdings Inc trades at $9.49 (market cap $28.05B). The key difference: Humana Inc is the larger of the two by market cap, and Nomura Holdings Inc pays the higher dividend (3.4%). Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 53 Days and Nomura Holdings Inc for 55 Days on average.
| HUM | NMR | |
|---|---|---|
Market Cap | $47.61B | $28.05B |
Volume | 1,827,332 | 729,574 |
Sector | Health | Financials |
52-Week High | $409.85 | $10.86 |
52-Week Low | $163.67 | $6.73 |
Typical Hold Time | 53 Days | 55 Days |
Enterprise Value | $54.97B | $38.55T |
Dividend Yield | 0.89% | 3.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $387.12, down 4.24% today, but maintains a bullish technical outlook with strong institutional support. The stock shows mixed fundamentals with revenue growth to $129.66B in 2025 but declining profit margins at 0.88%. Recent analyst upgrades, including Barclays' $515 target on September 25, 2026, highlight optimism despite ongoing Medicare Advantage plan adjustments affecting member transitions.
Investment outlook remains cautiously optimistic with a consensus price target of $432.63 offering 12% upside. Risks include margin compression, regulatory scrutiny from Medicare billing practices, and competitive pressures in managed care. The company's strong cash position of $20.44B and consistent dividend payments provide stability amid enrollment volatility.
Nomura Holdings (NMR) trades at $9.54, down 2.45% today, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with revenue growth from $1.38T in 2024 to $1.66T in 2025 and net income surging to $340.74B. Valuation metrics appear attractive with P/E of 11.29 and P/B of 1.15, while analyst consensus leans toward Hold (66.67%) with some positive momentum coverage from Zacks.
The outlook presents a mixed picture - strong profitability and reasonable valuation support upside potential, but negative operating cash flows and increasing debt-to-asset ratios pose significant risks. Recent technical weakness suggests near-term pressure, though fundamental strength could drive recovery if earnings momentum continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
